Fiona Hegi-Johnson, Stacey E Rudd, Christian W Wichmann, Tim Akhurst, Peter Roselt, Sandra Sursock, Jenny Trinh, Thomas John, Lisa Devereux, Paul S Donnelly, Rodney J Hicks, Andrew M Scott, Daniel Steinfort, Stephen Fox, Benjamin Blyth, Sagun Parakh, Gerard G Hanna, Jason Callahan, Kate Burbury, Michael MacManus
INTRODUCTION: ImmunoPET is a multicenter, single arm, phase 0-1 study of 89 Zr-DFO-Sq-durvalumab (89 Zr-durvalumab), a novel PET tracer, designed to interrogate the expression of PD-L1 in patients with NSCLC. Clinically relevant findings from phase 0 are presented here. METHODS: Phase 0 was designed to investigate tracer biodistribution and safety in patients with metastatic NSCLC with PD-L1 expression >25%. After 60MBq/70kg 89 Zr-durvalumab infusion, PET/CT images were acquired at days 0, 1, 3 or 5 ± 24h...
July 3, 2023: International Journal of Radiation Oncology, Biology, Physics